A recent Plain Language Summary of Publication stated ImmunityBio Inc.'s newly approved Anktiva® (N-803) plus Bacillus Calmette-Guérin (BCG) vaccine combination therapy produced positive results for certain bladder cancer patients.
Postexposure Prophylaxis With Nirmatrelvir-Ritonavir Does Not Cut COVID-19 Infection
No significant reduction seen in risk for symptomatic SARS-CoV-2 infection with postexposure prophylaxis for five or 10 days
Accelerated Progression to T1D During Pandemic Seen for Presymptomatic Youth
Incidence rate of type 1 diabetes significantly increased after COVID-19 infection
Severity of COVID-19 Reinfection Linked to Severity of Initial Infection
Within the same epoch, long COVID diagnoses occur more often following initial infection than reinfection